share_log

Rodman & Renshaw Reiterates Buy on Emergent BioSolutions, Maintains $16 Price Target

Benzinga ·  Sep 13 23:48  · Ratings

Rodman & Renshaw analyst Brandon Folkes reiterates Emergent BioSolutions (NYSE:EBS) with a Buy and maintains $16 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment